Application for Aphanamgrandiol A in preparation of medicines for treating chronic obstructive pulmonary disease
A technology for chronic obstructive pulmonary diseases, applied in drug combinations, respiratory diseases, pharmaceutical formulations, etc., can solve problems such as difficult to obtain satisfactory curative effect, different pathogenesis, slow progress in drug treatment research, etc., to achieve outstanding substantive features, strong inhibitory effect
- Summary
- Abstract
- Description
- Claims
- Application Information
AI Technical Summary
Problems solved by technology
Method used
Image
Examples
Embodiment 1
[0012] Embodiment 1: the preparation of the compound Aphanamgrandiol A tablet involved in the present invention:
[0013] Take 5 grams of compound Aphanamgrandiol A, add 195 grams of dextrin, mix well, and make 1000 tablets by conventional compression.
Embodiment 2
[0014] Embodiment 2: the preparation of compound Aphanamgrandiol A capsules involved in the present invention:
[0015] Get 5 grams of compound Aphanamgrandiol A, add 195 grams of starch, mix well, pack into capsules and make 1000 capsules.
[0016] The following pharmacodynamic experiments will further illustrate its drug activity.
[0017] Methods: SPF grade female BALB / c mice, 18-20g, were randomly divided into normal control group, model control group, positive control group (terbutaline, 10mg / kg, intragastric administration), drug treatment group (Aphanamgrandiol A 5, 10, 20mg / kg, intragastric administration), 10 rats in each group. Put the mice in a 4L container, smoke daily (Jinjian brand cigarettes, tar content less than 16mg), five times a week, for four consecutive weeks, and administer the drug by intragastric administration 1 hour before daily smoking. One hour after fumigation, anesthetize with sodium phenobarbital, perfuse the lungs with 0.6 mL of pre-cooled PB...
experiment example 1
[0018] Experimental example 1: Aphanamgrandiol A inhibits the production of inflammatory mediators in bronchoalveolar lavage fluid (BALF) of COPD mice
[0019] (1) Inhibitory effect of Aphanamgrandiol A on TNFα production in BALF of COPD mice
[0020] The proinflammatory cytokine TNFα is an initiating factor in the pathogenesis of COPD. The level of TNFα in COPD patients is higher than that of normal people, and the cultured bronchial epithelial cells can secrete TNFα in contact with cigarette smoke. TNFα can promote neutrophil degranulation, induce mucosal cell proliferation and hypersecretion, increase the production of IL-8 in epithelial cells, increase the production of matrix metalloproteinases in macrophages, and promote airway hyperresponsiveness. The purpose of this experiment is to investigate the effect of Aphanamgrandiol A on the production of TNFα in the BALF of COPD mice. The results are shown in Table 1.
[0021] Table 1 Effect of Aphanamgrandiol A on TNFα prod...
PUM

Abstract
Description
Claims
Application Information

- R&D
- Intellectual Property
- Life Sciences
- Materials
- Tech Scout
- Unparalleled Data Quality
- Higher Quality Content
- 60% Fewer Hallucinations
Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2025 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com